Piedmont Research Center
Piedmont Research Center ("Piedmont") is a contract research service organization focused on developing our clients' product pipelines through the efficient, timely and cost effective evaluation of potential anti-cancer agents. Our highly responsive and expert staff provide a full spectrum of in vivo and in vitro research services and products.
Located in the heart of Research Triangle Park, North Carolina, Piedmont Research Center was founded in 1997. In 2002, Piedmont became the wholly owned subsidiary of PPD. After five years of substantial growth, it was acquired by Charles River Laboratories International, Inc. in May, 2009. Our 80+ on-site staff operate from our 28,000 square foot AAALAC accredited facility. AALAS certified staff ensure the conduct of our high quality in vivo studies that are the hallmark of Piedmont.
We seek long-term relationships with our clients by being highly responsive to their changing needs; providing them with expert assistance; and focusing on innovation to enhance mutual growth.
Superior drug-discovery and development expertise allows the Piedmont staff to respond to and anticipate changing industry needs. In doing so, we continually explore and develop new means to enhance research capabilities and applications.
Piedmont provides drug discovery and development services through the design and conduct of in vitro and in vivo studies. Utilizing models of cancer; angiogenesis; toxicity; pharmacokinetics and pharmacodynamics, investigational agents are evaluated as primary, combination, and adjuvant chemotherapies.
Responding to the industry and research community's need for quality, reliability and consistency in research products, Piedmont has leveraged its preclinical expertise and expanded to offer cryopreserved mouse and rat hepatocytes, tumor powders, plasma and serum.